Navigation Links
Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
Date:2/25/2008

PHOENIX, Feb. 25 /PRNewswire/ -- Associated Foot & Ankle Specialists today announced it is recruiting patients with foot ulcers due to diabetes to participate in the MATRIX clinical trial. The trial will study the effects of a new product, Excellarate, for the potential treatment of patients with non-healing diabetic foot ulcers. Excellarate is an investigational product designed to stimulate the process of wound healing.

The MATRIX trial is a randomized, double-blind safety and efficacy research study in which Excellarate is topically administered once or twice over the course of the study, with a goal of complete ulcer closure at 12 weeks or earlier.

"The Excellarate topical gel, using Gene Activated Matrix (GAM) technology is designed to provide release of the platelet-derived growth factor BB protein, which stimulates angiogenesis (the growth of new blood vessels) and granulation tissue formation, the building blocks for a variety of wound healing processes," stated Arthur J. Tallis, D.P.M., Podiatric Physician & Surgeon at Associated Foot & Ankle Specialists and a trial investigator.

There are currently more than 20 million Americans who have diabetes and this number is expected to double by the year 2030. Many diabetic patients suffer from peripheral neuropathy, or a loss of feeling in their feet, that puts them at increased risk of foot ulceration. Over 850,000 chronic diabetic ulcers are diagnosed in the U.S. each year. Patients with non-healing ulcers are more susceptible to infections that may lead to amputation of the affected foot or leg.

Associated Foot & Ankle Specialists is among only 25 sites participating in the MATRIX trial. The trial is expected to enroll 210 patients nationwide. Prospective participants can contact Norma Ramos at Associated Foot & Ankle Specialists, Phoenix, Arizona, at 602-274-4100 for more information about the study and eligibility.


'/>"/>
SOURCE Associated Foot & Ankle Specialists
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
2. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
3. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
4. Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
5. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
6. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
7. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
8. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
9. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
10. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Stock-Callers.com today evaluates the following Drug ... Novo Nordisk A/S (NYSE: NVO ), Sucampo Pharmaceuticals ... Inc. (NASDAQ: PTX ). These stocks belong to ... , 2017, finishing near its session lows. As per a ... while shares of health care companies in the S&P 500 ...
(Date:1/20/2017)... 2017 Avillion LLP, a co-developer and financier ... Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg will ... . ... Weinberg has spent more than 17 years as a pharmaceutical and ... micro-cap biotech. Over the course of his career, he has interfaced ...
(Date:1/19/2017)... , Jan. 19, 2017 The U.S. Food ... of Chronic Idiopathic Constipation (CIC) in adult patients. ... chronic gastrointestinal disorders," said Julie Beitz , M.D., director ... Center for Drug Evaluation and Research. "With the availability of ... appropriate treatment for their condition." ...
Breaking Medicine Technology:
(Date:1/21/2017)... Viejo, California (PRWEB) , ... January 21, 2017 , ... "ProDOF is the perfect set ... one subject to another subject in a scene," said Christina Austin - CEO of Pixel ... a given scene. Easily create the illusion of a DSLR racking focus from one ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to take an ... of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a ... Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel to cleanse ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... Redwood Family Dermatology has recently joined their multi-specialty medical group. The ... range of cosmetic services. , “We’re excited to add this excellent dermatology practice ...
(Date:1/21/2017)... ... 21, 2017 , ... In the United States, 20 million women and 10 ... they often feel shame for having struggled with an eating disorder as well as ... “Rising Strong in Life After an Eating Disorder” -- to be featured at this ...
(Date:1/20/2017)... ... ... New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool lift is ... be wheeled out of the way and stored when not in use. It is freestanding ... feedback from customers into specific enhancements and created a new product that is built directly ...
Breaking Medicine News(10 mins):